Wikipedia

Diabetic foot ulcer

(Redirected from Neuropathic ulcer)

Diabetic foot ulcer is a breakdown of the skin and sometimes deeper tissues of the foot that leads to sore formation. It is thought to occur due to abnormal pressure or mechanical stress chronically applied to the foot, usually with concomitant predisposing conditions such as peripheral sensory neuropathy, peripheral motor neuropathy, autonomic neuropathy or peripheral arterial disease.[1] It is a major complication of diabetes mellitus, and it is a type of diabetic foot disease. Secondary complications to the ulcer, such as infection of the skin or subcutaneous tissue, bone infection, gangrene or sepsis are possible, often leading to amputation.[1]

Diabetic foot ulcer
Neuropathic diabetic foot ulcer
Causesdiabetes

A key feature of wound healing is stepwise repair of lost extracellular matrix (ECM), the largest component of the dermal skin layer.[2] However, in some cases, physiological insult or disorder - in this case, diabetes mellitus - impedes the wound healing process. In diabetic wounds, the inflammatory phase of the healing process is prolonged, delaying the formation of mature granulation tissue and reducing the healing wound's tensile strength.[3]

Treatment of diabetic foot ulcers includes blood sugar control, removal of dead tissue from the wound, wound dressings, and removing pressure from the wound through techniques such as total contact casting. Surgery in some cases may improve outcomes.[4] Hyperbaric oxygen therapy may also help but is expensive.[4]

34% of people with diabetes develop a diabetic foot ulcer during their lifetime, and 84% of all diabetes-related lower-leg amputations are associated with or result from diabetic foot ulcers.[5]

Risk factors

edit

Risk factors implicated in the development of diabetic foot ulcers are infection, older age,[6] diabetic neuropathy,[7] peripheral vascular disease, cigarette smoking, poor glycemic control, previous foot ulcerations[7] or amputations,[5] and ischemia of small and large blood vessels.[8][9] Prior history of foot  disease, foot deformities that produce abnormally high forces of pressure, callus at pressure areas[7]  renal failure, oedema, impaired ability to look after personal care (e.g. visual impairment) are further risk factors for diabetic foot ulcer.[6][5]

People with diabetes often develop diabetic neuropathy due to several metabolic and neurovascular factors. Peripheral neuropathy causes loss of pain or feeling in the toes, feet, legs, and arms due to distal nerve damage and low blood flow. Autonomic neuropathy causes Sudomotor dysfunction and dryness of the skin. Blisters and sores may appear on numb areas of the feet and legs, such as metatarsophalangeal joints and the heel region, as a result of pressure or injury which may go unnoticed and eventually become a portal of entry for bacteria and infection.[citation needed]

Pathophysiology

edit

Extracellular matrix

edit

Extra cellular matrix (or "ECM") is the external structural framework that cells attach to in multicellular organisms. The dermis lies below the epidermis, and these two layers are collectively known as the skin. Dermal skin is primarily a combination of fibroblasts growing in this matrix. The specific species of ECM of connective tissues often differ chemically, but collagen generally forms the bulk of the structure.[citation needed]

Through the interaction of a cell with its extracellular matrix (transmitted through the anchoring molecules classed as integrins) there forms a continuous association between the cell interior, cell membrane and its extracellular matrix components that helps drive various cellular events in a regulated fashion.[10] Wound healing is a localized event involving the reaction of cells to the damage sustained.[citation needed]

The cells break down damaged ECM and replace it, generally increasing in number to react to the harm. The process is activated, though perhaps not exclusively, by cells responding to fragments of damaged ECM, and the repairs are made by reassembling the matrix by cells growing on and through it. Because of this, extracellular matrix is often considered as a 'conductor of the wound healing symphony'.[11] In the Inflammatory phase, neutrophils and macrophages recruit and activate fibroblasts which in subsequent granulation phase migrate into the wound, laying down new collagen of the subtypes I and III.[citation needed]

In the initial events of wound healing, collagen III predominates in the granulation tissue which later on in remodeling phase gets replaced by collagen I giving additional tensile strength to the healing tissue.[12][13] It is evident from the known collagen assembly that the tensile strength is basically due to fibrillar arrangement of collagen molecules, which self-assemble into microfibrils in a longitudinal as well as lateral manner producing extra strength and stability to the collagen assembly.[13][14] Metabolically altered collagen is known to be highly inflexible and prone to break down, particularly over pressure areas. Fibronectin is the major glycoprotein secreted by fibroblasts during initial synthesis of extracellular matrix proteins. It serves important functions, being a chemo-attractant for macrophages, fibroblasts and endothelial cells.[citation needed]

The basement membrane that separates the epidermis from the dermal layer and the endothelial basement membrane mainly contains collagen IV that forms a sheet and binds to other extracellular matrix molecules like laminin and proteoglycans. In addition to collagen IV, the epidermal and endothelial basement membrane also contains laminin, perlecan and nidogen.[13][14] Hyaluronic acid, a pure glycosaminoglycan component, is found in high amounts in damaged or growing tissues. It stimulates cytokine production by macrophages and thus promotes angiogenesis. In normal skin chondroitin sulfate proteoglycan is mainly found in the basement membrane, but in healing wounds they are up-regulated throughout the granulation tissue especially during the second week of wound repair where they provide a temporary matrix with highly hydrative capacity.[15] Binding of growth factors is clearly an important role of perlecan in wound healing and angiogenesis. Poor wound healing in diabetes mellitus may be related to perlecan expression. High levels of glucose can decrease perlecan expression in some cells, probably through transcriptional and post-transcriptional modification.[15][16] Wound healing phases especially, granulation, re-epithelization and remodelling exhibit controlled turnover of extracellular matrix components.[citation needed]

Altered metabolism

edit

Diabetes mellitus is a metabolic disorder and hence the defects observed in diabetic wound healing are thought to be the result of altered protein and lipid metabolism and thereby abnormal granulation tissue formation.[17] Increased glucose levels in the body end up in uncontrolled covalent bonding of aldose sugars to a protein or lipid without any normal glycosylation enzymes.[18] These stable products then accumulate over the surface of cell membranes, structural proteins and circulating proteins. These products are called advanced glycation endproducts (AGEs) or Amadori products. Formation of AGEs occurs on extracellular matrix proteins with slow turnover rate. AGEs alter the properties of matrix proteins such as collagen, vitronectin, and laminin through AGE-AGE intermolecular covalent bonds or cross-linking.[18][19][20] AGE cross-linking on type I collagen and elastin results in increased stiffness. AGEs are also known to increase synthesis of type III collagen that forms the granulation tissue. AGEs on laminin result in reduced binding to type IV collagen in the basement membrane, reduced polymer elongation and reduced binding of heparan sulfate proteoglycan.[18]

Impaired NO synthesis
Nitric oxide is known as an important stimulator of cell proliferation, maturation and differentiation. Thus, nitric oxide increases fibroblast proliferation and thereby collagen production in wound healing. Also, L-arginine and nitric oxide are required for proper cross linking of collagen fibers, via proline, to minimize scarring and maximize the tensile strength of healed tissue.[21] Endothelial cell specific nitric oxide synthase (EcNOS) is activated by the pulsatile flow of blood through vessels. Nitric oxide produced by EcNOS, maintains the diameter of blood vessels and proper blood flow to tissues. In addition to this, nitric oxide also regulates angiogenesis, which plays a major role in wound healing.[22] Thus, diabetic patients exhibit reduced ability to generate nitric oxide from L-arginine. Reasons that have been postulated in the literature include accumulation of nitric oxide synthase inhibitor due to high glucose associated kidney dysfunction and reduced production of nitric oxide synthase due to ketoacidosis observed in diabetic patients and pH dependent nature of nitric oxide synthase.[18][23]
Structural and functional changes in fibroblasts
Diabetic ulcer fibroblasts show various morphological differences compared to fibroblasts from age matched controls. Diabetic ulcer fibroblasts are usually large and widely spread in the culture flask compared to the spindle shaped morphology of the fibroblasts in age-matched controls. They often show dilated endoplasmic reticulum, numerous vesicular bodies and lack of microtubular structure in transmission electron microscopy study. Therefore, interpretation of these observations would be that in spite of high protein production and protein turnover in diabetic ulcer fibroblasts, vesicles containing secretory proteins could not travel along the microtubules to release the products outside.[24][25] Fibroblasts from diabetic ulcer exhibit proliferative impairment that probably contributes to a decreased production of extracellular matrix proteins and delayed wound contraction and impaired wound healing.[24]
Increased matrix metalloproteinases (MMP) activity
In order for a wound to heal, extracellular matrix not only needs to be laid down but also must be able to undergo degradation and remodeling to form a mature tissue with appropriate tensile strength.[26] Proteases, namely matrix metalloproteinases are known to degrade almost all the extracellular matrix components. They are known to be involved in fibroblast and keratinocyte migration, tissue re-organization, inflammation and remodeling of the wounded tissue.[3][26] Due to persistently high concentrations of pro-inflammatory cytokines in diabetic ulcers, MMP activity is known to increase by 30 fold when compared to acute wound healing.[27] MMP-2 and MMP-9 show sustained overexpression in chronic non-healing diabetic ulcers.[3][28] Balance in the MMP activity is usually achieved by tissue inhibitor of metalloproteinases (TIMP). Rather than absolute concentrations of either two, it is the ratio of MMP and TIMP that maintains the proteolytic balance and this ratio is found to be disturbed in diabetic ulcer.[29][30] In spite of these findings, the exact mechanism responsible for increased MMP activity in diabetes is not known yet. One possible line of thought considers Transforming growth factor beta (TGF-β) as an active player. Most MMP genes have TGF-β inhibitory element in their promoter regions and thus TGF–β regulates the expression of both MMP and their inhibitor TIMP.[31] In addition to the importance of cell-cell and cell-matrix interactions, all phases of wound healing are controlled by a wide variety of different growth factors and cytokines. To mention precisely, growth factors promote switching of early inflammatory phase to the granulation tissue formation. Decrease in growth factors responsible for tissue repair such as TGF-β is documented in diabetic wounds. Thus, reduced levels of TGFβ in diabetes cases lower down the effect of inhibitory regulatory effect on MMP genes and thus cause MMPs to over express.[32][33][34]

Biomechanics

edit

Complications in the diabetic foot and foot-ankle complex are wider and more destructive than expected and may compromise the structure and function of several systems: vascular, nervous, somatosensory, musculoskeletal. Thus, deeper comprehension of the alteration of gait and foot biomechanics in the diabetic foot is of great interest and may play a role in the design and onset of preventive as well as therapeutic actions.[citation needed]

Briefly, the effect of diabetes on the main structures of the foot-ankle complex can be summarised as:

  • effects on the skin: skin – and the soft tissues immediately underneath the skin – undergo greater compression and shear loading than usual, thus explaining the onset of tissue damage so deeply correlated to traumatic ulceration processes. Besides this, skin of the diabetic foot loses autonomic nervous control and consequently reduced hydration, making it less elastic and thus more vulnerable to the action of increased mechanical stress;
  • effects on tendons and ligaments: protein glycosylation and the resulting collagen abnormalities lead to greater transversal section – i.e. thickening – of tendons and ligaments and a greater coefficient of elasticity. Particularly affected by this process are Plantar Fascia and Achilles Tendon. Both causes lead to increased stiffness of those structures;
  • effects on cartilage: similar to what happens to tendons and ligaments, cartilage changes its composition mainly due to the modification of collagen fibers. This increases its stiffness and decreases the range of motion of all joints in the foot and ankle.
  • effects on muscles: Diabetes mellitus causes severe damage to nerve conduction, thus causing a worsening in the management of the related muscle fibers. As a consequence, both intrinsic and extrinsic muscles of the foot-ankle complex are damaged in structure (reduction of muscle volume) and function (reduction of muscle strength);
  • effects on the peripheral sensory system: impaired nerve conduction has a dramatic effect on the peripheral sensory system since it leads to loss of protective sensation under the sole of the foot. This exposes the diabetic foot to thermal or mechanical trauma, and to the late detection of infection processes or tissue breakdown;
  • effects on foot morphology (deformities): due to most of the above alterations, a significant imbalance of peripheral musculature and soft tissue occur in the foot which seriously alters its morphology and determines the onset of foot deformities. Most common deformities of the diabetic foot are represented by a high longitudinal arch (rigid cavus foot), hammer toes and hallux valgus. A completely different morphologic degeneration is represented by neuropathic arthropathy, whose analysis is not part of this discussion.[35][36][37][38][39]

Diagnosis

edit

Assessment of diabetic foot ulcer includes identifying risk factors such as diabetic peripheral neuropathy, noting that 50 percent of people are asymptomatic, and ruling out other causes of peripheral neuropathy such as alcohol use disorder and spinal injury.[6] Diabetic foot ulcers are often misdiagnosed in patients with undiagnosed skin malignancies, especially high-risk in elderly patients.[40][41]

The location of the ulcer, its size, shape, depth and whether the tissue is granulating or sloughy needs to be considered. Further considerations include whether there is malodour, condition of the border of the wound and palpable bone and sinus formation should be investigated. Signs of infection require to be considered such as development of grey or yellow tissue, purulent discharge, unpleasant smell, sinus, undermined edges and exposure of bone or tendon.[42]

Classification

edit

Diabetic foot ulcer is a complication of diabetes. Diabetic foot ulcers are classified as either neuropathic, neuroischaemic or ischaemic.[42]

Doctors also use the Wagner Grades to describe the severity of an ulcer. The purpose of the Wagner Grades is to allow specialists to better monitor and treat diabetic foot ulcers. This grading system classifies Diabetic foot ulcers using numbers, from 0 to 5.

Wagner Grades 0 through 5 are as follows:[citation needed]

  • 0. No diabetic foot ulcer is present, but there is a high risk of developing one.
  • 1. A surface ulcer involves full skin thickness, but does not yet involve the underlying tissues.
  • 2. A deep ulcer penetrates past the surface, down to the ligaments and muscle. There is no abscess or bone involved yet.
  • 3. A deep ulcer occurs with inflammation of subcutaneous connective tissue or an abscess. This can include infections in the muscle, tendon, joint, and/or bone.
  • 4. The tissue around the area of the ulcer (limited to the toes and forefoot) has begun to decay. This condition is called gangrene.
  • 5. Gangrene has spread from the localized area of the ulcer to become extensive. This involves the whole foot.

[43]

Prevention

edit
 
Many diabetic shoes have velcro closures for ease of application and removal.

Steps to prevent diabetic foot ulcers include frequent review by a foot specialist and multidisciplinary team,[7] good foot hygiene, diabetic socks[44] and shoes, as well as avoiding injury. Foot-care education combined with increased surveillance can reduce the incidence of serious foot lesions.[45]

There is no high quality researches that evaluate complex intervention of combining two or more preventive strategies in preventing diabetic foot ulcer.[46]

Monitoring and prediction

edit

People with loss of feeling in their feet should inspect their feet on a daily basis, to ensure that there are no wounds starting to develop.[47][48] Monitoring a person's feet can help in predicting the likelihood of developing ulcers.[citation needed]

A common method for this is using a special thermometer to look for spots on the foot that have higher temperature which indicate the possibility of an ulcer developing.[49] At the same time there is no strong scientific evidence supporting the effectiveness of at-home foot temperature monitoring.[50]

The current guideline in the United Kingdom recommends collecting 8-10 pieces of information for predicting the development of foot ulcers.[51] A simpler method proposed by researchers provides a more detailed risk score based on three pieces of information (insensitivity, foot pulse, previous history of ulcers or amputation). This method is not meant to replace people regularly checking their own feet but complement it.[49][52]

Footwear

edit

Diabetic shoes, insoles and socks are personalised products that relieve pressure on the foot in order to prevent ulcers.[53] The evidence for special footwear to treat foot ulcers is poor[54] but their effectiveness for prevention is well-established.[55][56][57] Design features of footwear that are effective in reducing pressure are arch supports, cushioned cut-outs around points at risk of damage, and cushioning at the ball of the foot. Technology for measuring the pressure within the shoes is recommended during designing diabetic footwear.[58][59]

People with loss of feeling in their feet should not walk around barefoot, but use proper footwear at all times.

Treatment

edit

Foot ulcers in diabetes require a multidisciplinary team that may include the primary care doctor, a diabetes nurse specialist, a tissue viability nurse,[42] podiatrists, vascular surgeons, diabetes specialists and surgeons.[1] An aim to improve glycemic  control, if poor, may slow disease progression.[6] When osteomyelitis is suspected to be involved in the foot, but not evidenced on an x-ray, an MRI scan should be obtained.[42] In those with a high likelihood of osteomyelitis, a combination of x-ray and being able to probe to bone can reliably diagnose osteomyelitis without the need for more advanced imaging.[1] A bone biopsy with culture is the gold standard for diagnosing osteomyelitis.[1]

With regards to infected foot ulcers, the presence of microorganisms is not in itself enough to determine whether an infection is present. Signs of an infection such as erythema, purulence, fluctuance, swelling, warmth, or discharge should also be present. The most common organism causing infection is staphylococcus.[5] The treatment consists of debridement, appropriate bandages, managing peripheral arterial disease and appropriate use of antibiotics[5] (against pseudomonas aeruginosa, staphylococcus, streptococcus and anaerobe strains), and arterial revascularization if necessary.

Antibiotics

edit

The length of antibiotic courses depend on the severity of the infection and whether bone infection is involved but can range from 1 week to 6 weeks or more. Current recommendations are that antibiotics are only used when there is evidence of infection and continued until there is evidence that the infection has cleared, instead of evidence of ulcer healing. Choice of antibiotic depends on common local bacterial strains known to infect ulcers. Microbiological swabs are believed to be of limited value in identifying causative strain.[6] Microbiological investigation is of value in cases of osteomyelitis.[42] Most ulcer infections involve multiple microorganisms.[5]

There is limited safety and efficacy data of topical antibiotics in treating diabetic foot ulcers.[60]

Wound dressings

edit

There are many types of dressings used to treat diabetic foot ulcers such as absorptive fillers, hydrogel dressings, and hydrocolloids.[61] There is no good evidence that one type of dressing is better than another for diabetic foot ulcers.[62] In selecting dressings for chronic non healing wounds it is recommended that the cost of the product be taken into account.[63]

Hydrogel dressings may have shown a slight advantage over standard dressings, but the quality of the research is of concern.[64][65] Dressings and creams containing silver have not been properly studied[66] nor have alginate dressings.[67] Biologically active bandages that combine hydrogel and hydrocolloid traits are available, however more research needs to be conducted as to the efficacy of this option over others.[61]

Total contact casting

edit

Total contact casting (TCC) is a specially designed cast designed to take weight of the foot (off-loading) in patients with DFUs. Reducing pressure on the wound by taking weight of the foot has proven to be very effective in DFU treatment. DFUs are a major factor leading to lower leg amputations among the diabetic population in the US with 85% of amputations in diabetics being preceded by a DFU.[68] Furthermore, the 5 year post-amputation mortality rate among diabetics is estimated at 45% for those with neuropathic DFUs.[68]

TCC has been used for off-loading DFUs in the US since the mid-1960s and is regarded by many practitioners as the "reference standard" for off-loading the bottom surface (sole) of the foot.[69]

TCC helps patients to maintain their quality of life. By encasing the patient's complete foot — including the toes and lower leg — in a specialist cast to redistribute weight and pressure from the foot to the lower leg during everyday movements, patients can remain mobile.[70] The manner in which TCC redistributes pressure protects the wound, letting damaged tissue regenerate and heal.[71] TCC also keeps the ankle from rotating during walking, which helps prevent shearing and twisting forces that can further damage the wound.[72]

Effective off loading is a key treatment modality for DFUs, particularly those where there is damage to the nerves in the feet (peripheral neuropathy). Along with infection management and vascular assessment, TCC is vital aspect to effectively managing DFUs.[72] TCC is the most effective and reliable method for off-loading DFUs.[73][74][75]

A 2013 meta-analysis by the Cochrane Collaboration compared the effectiveness of non-removable pressure relieving interventions, such as casts, with therapeutic shoes, dressings, removable pressure relieving orthotic devices, and surgical interventions. Non-removable pressure relieving interventions, including non-removable casts with an Achilles tendon lengthening component, were found to be more effective at healing foot ulcers related to diabetes that therapeutic shoes and other pressure relieving approaches.[76]

TCC systems include TCC-EZ (Integra LifeSciences) and Cutimed Off-loader (BSN Medical).[77]

Hyperbaric oxygen

edit

In 2015, a Cochrane review concluded that for people with diabetic foot ulcers, hyperbaric oxygen therapy reduced the risk of amputation and may improve the healing at 6 weeks.[78] However, there was no benefit at one year and the quality of the reviewed trials was inadequate to draw strong conclusions.[78]

Negative pressure wound therapy

edit
Main article: Negative pressure wound therapy

This treatment uses vacuum to remove excess fluid and cellular waste that usually prolong the inflammatory phase of wound healing. Despite a straightforward mechanism of action, results of negative pressure wound therapy studies have been inconsistent. Research needs to be carried out to optimize the parameters of pressure intensity, treatment intervals and exact timing to start negative pressure therapy in the course of chronic wound healing.[79]

There is low-certainty evidence that negative pressure wound therapy would improve wound healing in diabetic foot ulcers.[80]

Other treatments

edit

Ozone therapy – there is only limited and poor-quality information available regarding the effectiveness of ozone therapy for treating foot ulcers in people with diabetes.[81]

Growth factors - there is some low-quality evidence that growth factors may increase the likelihood that diabetic foot ulcers will heal completely.[82]

Continuous diffusion of oxygen (CDO) - CDO delivers continuous oxygen to an occluded, moist wound site at much lower flow rates of 3–12 mL/h for 24 h 7 days a week for up to several weeks or months, depending on the wound status.[83]

Phototherapy - there is very weak evidence to suggest that people with foot ulcers due to diabetes may have improved healing.[84] There is no evidence to suggest that phototherapy improves the quality of life for people with foot ulcers caused by diabetes.[84]

Sucrose-octasulfate impregnated dressing is recommended by the International Working Group on the Diabetic Foot Ulcer (IWGDF)[85] for the treatment of non-infected, neuro-ischaemic diabetic foot ulcers that do not show an improvement with a standard of care regimen[86]

Autologous combined leucocyte, platelet and fibrin as an adjunctive treatment, in addition to best standard of care is also recommended by IWGDF[87] However, there is only low quality evidence that such treatment is effective in treating diabetic foot ulcer.[88]

There is limited evidence that granulocyte colony-stimulating factor may not hasten the resolution of diabetic foot ulcer infection. However, it may reduce the need for surgical interventions such as amputations and hospitalizations.[89]

It is unknown that whether intensive or conventional blood glucose control is better for diabetic foot ulcer healing.[90]

A 2020 Cochrane systematic review evaluated the effects of nutritional supplements or special diets on healing foot ulcers in people with diabetes. The review authors concluded that it's uncertain whether or not nutritional interventions have an effect on foot ulcer healing and that more research is needed to answer this question.[91]

Skin grafting and tissue replacements can help to improve the healing of diabetic foot ulcer.[92]

A 2021 systematic review concluded that there was no strong evidence about the effects of psychological therapies on diabetic foot ulcer healing and recurrence.[93]

Epidemiology

edit

Approximately 34% of people with diabetes (Type 1 or Type 2 diabetes) will develop a foot ulcer in their lifetime.[1] 18.6 million people worldwide will develop a foot ulcer each year.[1] 15-20% of moderately to severely infected foot ulcers eventually lead to amputation, and the mortality rate of diabetic foot ulcers is 30% at 5 years with a mortality rate of 70% in those with a foot ulcer who receive an above the foot amputation.[1] Foot ulcers and amputations are associated with a reduced quality of life. In the United States; Black people, Native Americans, Hispanics and those living in rural areas or those with a lower socioeconomic status have an increased rate of amputations due to diabetic foot ulcers.[1]

Approximately 8.8 percent of hospital admissions of diabetic patients are for foot related problems, and such hospital admissions are about 13 days longer than for diabetics without foot related admissions.[5] Approximately 58% of ulcers recur within 3 years and up to 65% recur within 5 years, sometimes at a different location that the original ulcer.[79] Diabetic foot disease is the leading cause of non-traumatic lower limb amputations.[6]

Research

edit

Stem cell therapy may represent a treatment for promoting healing of diabetic foot ulcers.[94][95] Diabetic foot ulcers develop their own, distinctive microbiota. Investigations into characterizing and identifying the phyla, genera and species of nonpathogenic bacteria or other microorganisms populating these ulcers may help identify one group of microbiota that promotes healing.[96]

The recent advances in epigenetic modifications, with special focus on aberrant macrophage polarisation is giving increasing evidences that epigenetic modifications might play a vital role in changing the treatment of diabetic foot ulcer in the near future.[97]

References

edit
  1. ^ a b c d e f g h i Armstrong, David G.; Tan, Tze-Woei; Boulton, Andrew J. M.; Bus, Sicco A. (3 July 2023). "Diabetic Foot Ulcers: A Review". JAMA. 330 (1): 62–75. doi:10.1001/jama.2023.10578. PMC 10723802. PMID 37395769. S2CID 259314584.
  2. ^ Nomikos Iakovos N, et al. (2006). "Protective and Damaging Aspects of Healing: A Review". Wounds. 18 (7): 177–185.
  3. ^ a b c McLennan S, et al. (2006). "Molecular aspects of wound healing" (PDF). Primary Intention. 14 (1): 8–13. Archived from the original (PDF) on 2010-05-24. Retrieved 2009-05-28.
  4. ^ a b Yazdanpanah L, Nasiri M, Adarvishi S (February 2015). "Literature review on the management of diabetic foot ulcer". World Journal of Diabetes. 6 (1): 37–53. doi:10.4239/wjd.v6.i1.37. PMC 4317316. PMID 25685277.
  5. ^ a b c d e f g Turns M (December 2013). "Diabetic foot ulcer management: the podiatrist's perspective" (PDF). British Journal of Community Nursing. 18: S14, S16-9. doi:10.12968/bjcn.2013.18.Sup12.S14. PMID 24796080.
  6. ^ a b c d e f Turns M (September 2012). "The diabetic foot: an overview for community nurses". British Journal of Community Nursing. 17 (9): 422, 424–27, 430–3. doi:10.12968/bjcn.2012.17.9.422. PMID 23123487.
  7. ^ a b c d Boulton AJ (2019-02-01). "The diabetic foot". Medicine. 47 (2): 100–105. doi:10.1016/j.mpmed.2018.11.001. ISSN 1357-3039.
  8. ^ Scott G (March–April 2013). "The diabetic foot examination: A positive step in the prevention of diabetic foot ulcers and amputation". Osteopathic Family Physician. 5 (2): 73–78. doi:10.1016/j.osfp.2012.08.002. S2CID 72816348.
  9. ^ Wu SC, Driver VR, Wrobel JS, Armstrong DG (2007). "Foot ulcers in the diabetic patient, prevention and treatment". Vascular Health and Risk Management. 3 (1): 65–76. PMC 1994045. PMID 17583176.
  10. ^ Hay E (1991). Cell biology of extracellular matrix second edition. New York: Plenum press. pp. 1–5. ISBN 978-0-306-40785-7.
  11. ^ Sweitzer SM, Fann SA, Borg TK, Baynes JW, Yost MJ (2006). "What is the future of diabetic wound care?". The Diabetes Educator. 32 (2): 197–210. doi:10.1177/0145721706286897. PMID 16554422. S2CID 34904588.
  12. ^ Schultz GS, Ludwig G, Wysocki A (2005). "Extracellular matrix: review of its roles in acute and chronic wounds". World Wide Wounds.
  13. ^ a b c Sussman C (2006). Wound Care:a collaborative practice manual third Edition. Lippincott Williams & Wilkins. pp. 21–47. ISBN 978-0-7817-7444-4.
  14. ^ a b Thomas DW, O'Neill ID, Harding KG, Shepherd JP (April 1995). "Cutaneous wound healing: a current perspective". Journal of Oral and Maxillofacial Surgery. 53 (4): 442–7. doi:10.1016/0278-2391(95)90721-1. PMID 7699500.
  15. ^ a b Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E (November 1998). "Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds". The Journal of Investigative Dermatology. 111 (5): 850–7. doi:10.1046/j.1523-1747.1998.00381.x. PMID 9804349.
  16. ^ US 7141551, Decarlo AA, Whitelock J, "Wound and cutaneous injury healing with a nucleic acid encoding perlecan.", published 28 November 2006 
  17. ^ Close-Tweedie J (June 2002). "Diabetic foot wounds and wound healing: a review". The Diabetic Foot. 5 (2): 68–76.
  18. ^ a b c d Goldin A, Beckman JA, Schmidt AM, Creager MA (August 2006). "Advanced glycation end products: sparking the development of diabetic vascular injury". Circulation. 114 (6): 597–605. doi:10.1161/CIRCULATIONAHA.106.621854. PMID 16894049.
  19. ^ Singh R, Barden A, Mori T, Beilin L (February 2001). "Advanced glycation end-products: a review". Diabetologia. 44 (2): 129–46. doi:10.1007/s001250051591. PMID 11270668.
  20. ^ Brownlee M (1995). "Advanced protein glycosylation in diabetes and aging". Annual Review of Medicine. 46: 223–34. doi:10.1146/annurev.med.46.1.223. PMID 7598459. S2CID 16119897.
  21. ^ Obayashi K, Akamatsu H, Okano Y, Matsunaga K, Masaki H (February 2006). "Exogenous nitric oxide enhances the synthesis of type I collagen and heat shock protein 47 by normal human dermal fibroblasts". Journal of Dermatological Science. 41 (2): 121–6. doi:10.1016/j.jdermsci.2005.08.004. PMID 16171977.
  22. ^ Duda DG, Fukumura D, Jain RK (April 2004). "Role of eNOS in neovascularization: NO for endothelial progenitor cells". Trends in Molecular Medicine. 10 (4): 143–5. doi:10.1016/j.molmed.2004.02.001. PMID 15162796.
  23. ^ Linden E, Cai W, He JC, Xue C, Li Z, Winston J, et al. (May 2008). "Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation". Clinical Journal of the American Society of Nephrology. 3 (3): 691–8. doi:10.2215/CJN.04291007. PMC 2386710. PMID 18256374.
  24. ^ a b Loots MA, Lamme EN, Mekkes JR, Bos JD, Middelkoop E (1999). "Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation". Archives of Dermatological Research. 291 (2–3): 93–9. doi:10.1007/s004030050389. PMID 10195396. S2CID 25658536.
  25. ^ Rowe DW, Starman BJ, Fujimoto WY, Williams RH (April 1977). "Abnormalities in proliferation and protein synthesis in skin fibroblast cultures from patients with diabetes mellitus". Diabetes. 26 (4): 284–90. doi:10.2337/diabetes.26.4.284. PMID 849809.
  26. ^ a b Ravanti L, Kähäri VM (October 2000). "Matrix metalloproteinases in wound repair (review)". International Journal of Molecular Medicine. 6 (4): 391–407. doi:10.3892/ijmm.6.4.391. PMID 10998429.
  27. ^ Vaalamo M, Leivo T, Saarialho-Kere U (July 1999). "Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing". Human Pathology. 30 (7): 795–802. doi:10.1016/s0046-8177(99)90140-5. PMID 10414498.
  28. ^ Wysocki AB, Staiano-Coico L, Grinnell F (July 1993). "Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9". The Journal of Investigative Dermatology. 101 (1): 64–8. doi:10.1111/1523-1747.ep12359590. PMID 8392530.
  29. ^ Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H (July 2002). "Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients". Diabetologia. 45 (7): 1011–6. doi:10.1007/s00125-002-0868-8. PMID 12136400.
  30. ^ Muller M, Trocme C, Lardy B, Morel F, Halimi S, Benhamou PY (April 2008). "Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing". Diabetic Medicine. 25 (4): 419–26. doi:10.1111/j.1464-5491.2008.02414.x. PMC 2326726. PMID 18387077.
  31. ^ McLennan SV, Fisher E, Martell SY, Death AK, Williams PF, Lyons JG, Yue DK (September 2000). "Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy". Kidney International. 77: S81-7. doi:10.1046/j.1523-1755.2000.07713.x. PMID 10997695.
  32. ^ Brem H, Tomic-Canic M (May 2007). "Cellular and molecular basis of wound healing in diabetes". The Journal of Clinical Investigation. 117 (5): 1219–22. doi:10.1172/JCI32169. PMC 1857239. PMID 17476353.
  33. ^ Bennett NT, Schultz GS (July 1993). "Growth factors and wound healing: Part II. Role in normal and chronic wound healing". American Journal of Surgery. 166 (1): 74–81. doi:10.1016/s0002-9610(05)80589-6. PMID 8392302.
  34. ^ Galkowska H, Wojewodzka U, Olszewski WL (2006). "Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers". Wound Repair and Regeneration. 14 (5): 558–65. doi:10.1111/j.1743-6109.2006.00155.x. PMID 17014667. S2CID 20859528.
  35. ^ Vileikyte L, Rubin RR, Peyrot M, Gonzalez JS, Boulton AJ, Ulbrecht JS, Cavanagh PR (April 2009). "Diabetic feet". The British Journal of General Practice. 59 (561): 290.1–290. doi:10.3399/bjgp09X420383. PMC 2662107. PMID 19341560.
  36. ^ Jeffcoate WJ, Lipsky BA, Berendt AR, Cavanagh PR, Bus SA, Peters EJ, et al. (December 2008). "Unresolved issues in the management of ulcers of the foot in diabetes". Diabetic Medicine. 25 (12): 1380–9. doi:10.1111/j.1464-5491.2008.02573.x. PMID 19046235. S2CID 24862107.
  37. ^ Bus SA, Valk GD, van Deursen RW, Armstrong DG, Caravaggi C, Hlavácek P, et al. (2008). "Specific guidelines on footwear and offloading". Diabetes/Metabolism Research and Reviews. 24 (Suppl 1): S192-3. doi:10.1002/dmrr.855. PMID 18442186. S2CID 34029708.
  38. ^ Bus SA, Valk GD, van Deursen RW, Armstrong DG, Caravaggi C, Hlavácek P, et al. (2008). "The effectiveness of footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in diabetes: a systematic review". Diabetes/Metabolism Research and Reviews. 24 (Suppl 1): S162-80. doi:10.1002/dmrr.850. PMID 18442178.
  39. ^ Ledoux W (2008). "Chapter 20: The Biomechanics of the Diabetic Foot". In Harris GF, Smith PA, Marks RM (eds.). Foot And Ankle Motion Analysis (Clinical Treatment and Technology). USA: CRC Press. pp. 317–401. ISBN 978-0-8493-3971-4.
  40. ^ Lyundup, A.V.; Balyasin, M.V.; Maksimova, N.V.; Kovina, M.V.; Krasheninnikov, M.E.; Dyuzheva, T.G.; Yakovenko, S.A.; Appolonova, S.A.; Schiöth, H.B.; Klabukov, I.D. (2022). "Misdiagnosis of diabetic foot ulcer in patients with undiagnosed skin malignancies". International Wound Journal. 19 (4): 871–887. doi:10.1111/iwj.13688. ISSN 1742-481X. PMC 9013580. PMID 34713964.
  41. ^ Detrixhe, Audrey; Libon, Florence; Mansuy, Marion; Nikkels-Tassoudji, Nazli; Rorive, Andrée; Arrese, Jorge E.; Quatresooz, Pascale; Reginster, Marie-Annick; Nikkels, Arjen F. (2016). "Melanoma masquerading as nonmelanocytic lesions". Melanoma Research. 26 (6): 631–634. doi:10.1097/CMR.0000000000000294. ISSN 1473-5636. PMID 27537773. S2CID 46766290.
  42. ^ a b c d e Turns M (2011). "The diabetic foot: an overview of assessment and complications". British Journal of Nursing. 20 (15): S19-25. doi:10.12968/bjon.2011.20.Sup8.S19. PMID 21841646.
  43. ^ Hamilton R, Hamilton J. "Diabetic Ulcers: Everything You Need to Know". Healing Your Wound. Retrieved September 6, 2018.
  44. ^ "Diabetic Socks - What is a Diabetic Sock & What Socks are Available". Diabetes.co.uk. 2019-01-15.
  45. ^ Litzelman DK, Slemenda CW, Langefeld CD, Hays LM, Welch MA, Bild DE, et al. (July 1993). "Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial". Annals of Internal Medicine. 119 (1): 36–41. doi:10.7326/0003-4819-119-1-199307010-00006. PMID 8498761. S2CID 35492751.
  46. ^ Hoogeveen RC, Dorresteijn JA, Kriegsman DM, Valk GD, et al. (Cochrane Wounds Group) (August 2015). "Complex interventions for preventing diabetic foot ulceration". The Cochrane Database of Systematic Reviews. 2015 (8): CD007610. doi:10.1002/14651858.CD007610.pub3. PMC 8504983. PMID 26299991.
  47. ^ "Foot Care". American Diabetes Association. Archived from the original on 2015-07-07. Retrieved 2015-08-04.
  48. ^ "Amputation and diabetes: How to protect your feet". Mayo Clinic.
  49. ^ a b "Simple tool identifies the people with diabetes most likely to develop foot ulcers". NIHR Evidence. National Institute for Health and Care Research. 2022-06-21. doi:10.3310/nihrevidence_51316. S2CID 251787297.
  50. ^ Golledge J, Fernando ME, Alahakoon C, Lazzarini PA, Aan de Stegge WB, van Netten JJ, Bus SA (September 2022). "Efficacy of at home monitoring of foot temperature for risk reduction of diabetes-related foot ulcer: A meta-analysis". Diabetes/Metabolism Research and Reviews. 38 (6): e3549. doi:10.1002/dmrr.3549. PMC 9541448. PMID 35605998. S2CID 251981184.
  51. ^ "Diabetic foot problems: prevention and management". National Institute for Health and Care Excellence (NICE). 26 August 2015. Retrieved 2022-09-06.
  52. ^ Chappell FM, Crawford F, Horne M, Leese GP, Martin A, Weller D, et al. (May 2021). "Development and validation of a clinical prediction rule for development of diabetic foot ulceration: an analysis of data from five cohort studies". BMJ Open Diabetes Research & Care. 9 (1): e002150. doi:10.1136/bmjdrc-2021-002150. PMC 8154962. PMID 34035053.
  53. ^ "Diabetes: putting people at the heart of services". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2022-07-26. doi:10.3310/nihrevidence_52026. S2CID 251299176.
  54. ^ Healy A, Naemi R, Chockalingam N (2014-09-18). "The effectiveness of footwear and other removable off-loading devices in the treatment of diabetic foot ulcers: a systematic review". Current Diabetes Reviews. 10 (4): 215–230. doi:10.2174/1573399810666140918121438. PMID 25245020.
  55. ^ Bus SA, van Deursen RW, Armstrong DG, Lewis JE, Caravaggi CF, Cavanagh PR (January 2016). "Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: a systematic review". Diabetes/Metabolism Research and Reviews. 32 (Suppl 1): 99–118. doi:10.1002/dmrr.2702. PMID 26342178. S2CID 24862853.
  56. ^ Heuch L, Streak Gomersall J (July 2016). "Effectiveness of offloading methods in preventing primary diabetic foot ulcers in adults with diabetes: a systematic review". JBI Database of Systematic Reviews and Implementation Reports. 14 (7): 236–265. doi:10.11124/JBISRIR-2016-003013. PMID 27532798. S2CID 12012686.
  57. ^ van Netten JJ, Raspovic A, Lavery LA, Monteiro-Soares M, Rasmussen A, Sacco IC, Bus SA (March 2020). "Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review" (PDF). Diabetes/Metabolism Research and Reviews. 36 (Suppl 1): e3270. doi:10.1002/dmrr.3270. PMID 31957213. S2CID 210830578.
  58. ^ Collings R, Freeman J, Latour JM, Paton J (January 2021). "Footwear and insole design features for offloading the diabetic at risk foot-A systematic review and meta-analyses". Endocrinology, Diabetes & Metabolism. 4 (1): e00132. doi:10.1002/edm2.132. PMC 7831212. PMID 33532602.
  59. ^ "Bespoke shoes and insoles could prevent foot ulcers in people with diabetes". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2020-08-05. doi:10.3310/alert_40657. S2CID 241787869.
  60. ^ Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J, et al. (Cochrane Wounds Group) (June 2017). "Topical antimicrobial agents for treating foot ulcers in people with diabetes". The Cochrane Database of Systematic Reviews. 6 (6): CD011038. doi:10.1002/14651858.CD011038.pub2. PMC 6481886. PMID 28613416.
  61. ^ a b Hilton JR, Williams DT, Beuker B, Miller DR, Harding KG (August 2004). "Wound dressings in diabetic foot disease". Clinical Infectious Diseases. 39 (Supplement 2): S100-3. doi:10.1086/383270. PMID 15306987.
  62. ^ Wu L, Norman G, Dumville JC, O'Meara S, Bell-Syer SE (July 2015). "Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews" (PDF). The Cochrane Database of Systematic Reviews. 2015 (7): CD010471. doi:10.1002/14651858.CD010471.pub2. PMC 7083265. PMID 26171906.
  63. ^ Dumville JC, Deshpande S, O'Meara S, Speak K (June 2013). "Foam dressings for healing diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 6 (6): CD009111. doi:10.1002/14651858.CD009111.pub3. PMC 7111297. PMID 23740766.
  64. ^ Dumville JC, O'Meara S, Deshpande S, Speak K (July 2013). "Hydrogel dressings for healing diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 7 (7): CD009101. doi:10.1002/14651858.CD009101.pub3. PMC 6486218. PMID 23846869.
  65. ^ Edwards J, Stapley S, et al. (Cochrane Wounds Group) (January 2010). "Debridement of diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 2010 (1): CD003556. doi:10.1002/14651858.CD003556.pub2. PMC 7144817. PMID 20091547.
  66. ^ Bergin SM, Wraight P (January 2006). "Silver based wound dressings and topical agents for treating diabetic foot ulcers". The Cochrane Database of Systematic Reviews (1): CD005082. doi:10.1002/14651858.CD005082.pub2. PMID 16437516.
  67. ^ Dumville JC, O'Meara S, Deshpande S, Speak K (June 2013). "Alginate dressings for healing diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 6 (6): CD009110. doi:10.1002/14651858.CD009110.pub3. PMC 7111427. PMID 23799857.
  68. ^ a b Margolis DJ, Malay DS, Hoffstad OJ, Leonard CE, MaCurdy T, de Nava KL, et al. (February 2011). "Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006 to 2008.". Data Points Publication Series [Internet]. Agency for Healthcare Research and Quality (US). PMID 22049565.
  69. ^ Armstrong DG, Lavery LA, Nixon BP, Boulton AJ (August 2004). "It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound". Clinical Infectious Diseases. 39 (Suppl 2): S92-9. doi:10.1086/383269. PMID 15306986.
  70. ^ Farid K, Farid M, Andrews CM (June 2008). "Total contact casting as part of an adaptive care approach: a case study". Ostomy/Wound Management. 54 (6): 50–65. PMID 18579926.
  71. ^ Raspovic A, Landorf KB (2014). "A survey of offloading practices for diabetes-related plantar neuropathic foot ulcers". Journal of Foot and Ankle Research. 7: 35. doi:10.1186/s13047-014-0035-8. PMC 4332025. PMID 25694793.
  72. ^ a b Snyder RJ, Frykberg RG, Rogers LC, Applewhite AJ, Bell D, Bohn G, et al. (November 2014). "The management of diabetic foot ulcers through optimal off-loading: building consensus guidelines and practical recommendations to improve outcomes". Journal of the American Podiatric Medical Association. 104 (6): 555–67. doi:10.7547/8750-7315-104.6.555. PMID 25514266.
  73. ^ Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB (June 2001). "Off-loading the diabetic foot wound: a randomized clinical trial". Diabetes Care. 24 (6): 1019–22. doi:10.2337/diacare.24.6.1019. PMID 11375363.
  74. ^ Lavery LA, Vela SA, Lavery DC, Quebedeaux TL (August 1996). "Reducing dynamic foot pressures in high-risk diabetic subjects with foot ulcerations. A comparison of treatments". Diabetes Care. 19 (8): 818–21. doi:10.2337/diacare.19.8.818. PMID 8842597. S2CID 24007485.
  75. ^ Lewis J, Lipp A (January 2013). "Pressure-relieving interventions for treating diabetic foot ulcers". The Cochrane Database of Systematic Reviews (1): CD002302. doi:10.1002/14651858.CD002302.pub2. PMID 23440787.
  76. ^ Lewis J, Lipp A (January 2013). "Pressure-relieving interventions for treating diabetic foot ulcers". The Cochrane Database of Systematic Reviews (1): CD002302. doi:10.1002/14651858.CD002302.pub2. PMID 23440787.
  77. ^ Ludwig K, Homer V, Jensen J (November 2019). "Ease of Application and Removal of Common Total-Contact Cast Systems Used in the Podiatric Medical Community". Journal of the American Podiatric Medical Association. 109 (6): 445–450. doi:10.7547/17-222. PMID 31755772. S2CID 208230168.
  78. ^ a b Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE, Weibel S (June 2015). "Hyperbaric oxygen therapy for chronic wounds" (PDF). The Cochrane Database of Systematic Reviews. 2015 (6): CD004123. doi:10.1002/14651858.CD004123.pub4. PMC 7055586. PMID 26106870.
  79. ^ a b Armstrong DG, Lavery LA, Abu-Rumman P, Espensen EH, Vazquez JR, Nixon BP, Boulton AJ (April 2002). "Outcomes of subatmospheric pressure dressing therapy on wounds of the diabetic foot". Ostomy/Wound Management. 48 (4): 64–8. PMID 11993062.
  80. ^ Liu Z, Dumville JC, Hinchliffe RJ, Cullum N, Game F, Stubbs N, et al. (Cochrane Wounds Group) (October 2018). "Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus". The Cochrane Database of Systematic Reviews. 2018 (10): CD010318. doi:10.1002/14651858.CD010318.pub3. PMC 6517143. PMID 30328611.
  81. ^ Liu J, Zhang P, Tian J, Li L, Li J, Tian JH, Yang K (October 2015). "Ozone therapy for treating foot ulcers in people with diabetes". The Cochrane Database of Systematic Reviews. 2015 (10): CD008474. doi:10.1002/14651858.CD008474.pub2. PMC 8246444. PMID 26505864.
  82. ^ Martí-Carvajal AJ, Gluud C, Nicola S, Simancas-Racines D, Reveiz L, Oliva P, Cedeño-Taborda J (October 2015). "Growth factors for treating diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 2015 (10): CD008548. doi:10.1002/14651858.CD008548.pub2. PMC 8665376. PMID 26509249.
  83. ^ Jiang H, Ochoa M, Jain V, Ziaie B (2018-08-28). "A laser-customizable insole for selective topical oxygen delivery to diabetic foot ulcers". MRS Communications. 8 (3): 1184–1190. doi:10.1557/mrc.2018.181. S2CID 258699243.
  84. ^ a b Wang HT, Yuan JQ, Zhang B, Dong ML, Mao C, Hu D (June 2017). "Phototherapy for treating foot ulcers in people with diabetes". The Cochrane Database of Systematic Reviews. 2017 (6): CD011979. doi:10.1002/14651858.CD011979.pub2. PMC 6481843. PMID 28657134.
  85. ^ "Wound healing interventions guideline". IWGDF Guidelines. 2019-05-25. Retrieved 2020-05-15.
  86. ^ Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, et al. (March 2018). "Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial". The Lancet. Diabetes & Endocrinology. 6 (3): 186–196. doi:10.1016/S2213-8587(17)30438-2. PMID 29275068.
  87. ^ Game F, Jeffcoate W, Tarnow L, Jacobsen JL, Whitham DJ, Harrison EF, et al. (November 2018). "LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial". The Lancet. Diabetes & Endocrinology. 6 (11): 870–878. doi:10.1016/S2213-8587(18)30240-7. PMID 30243803. S2CID 52341731.
  88. ^ Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Expósito JA, Bolíbar I, Rodríguez L, et al. (Cochrane Wounds Group) (May 2016). "Autologous platelet-rich plasma for treating chronic wounds". The Cochrane Database of Systematic Reviews. 2016 (5): CD006899. doi:10.1002/14651858.CD006899.pub3. PMC 9308064. PMID 27223580.
  89. ^ Cruciani M, Lipsky BA, Mengoli C, de Lalla F, et al. (Cochrane Wounds Group) (August 2013). "Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections". The Cochrane Database of Systematic Reviews (8): CD006810. doi:10.1002/14651858.CD006810.pub3. PMID 23955465.
  90. ^ Fernando ME, Seneviratne RM, Tan YM, Lazzarini PA, Sangla KS, Cunningham M, et al. (Cochrane Wounds Group) (January 2016). "Intensive versus conventional glycaemic control for treating diabetic foot ulcers". The Cochrane Database of Systematic Reviews. 2016 (1): CD010764. doi:10.1002/14651858.CD010764.pub2. hdl:1893/24156. PMC 8627701. PMID 26758576.
  91. ^ Moore ZE, Corcoran MA, Patton D (July 2020). "Nutritional interventions for treating foot ulcers in people with diabetes". The Cochrane Database of Systematic Reviews. 2020 (7): CD011378. doi:10.1002/14651858.cd011378.pub2. PMC 7388930. PMID 32677037.
  92. ^ Santema TB, Poyck PP, Ubbink DT, et al. (Cochrane Wounds Group) (February 2016). "Skin grafting and tissue replacement for treating foot ulcers in people with diabetes". The Cochrane Database of Systematic Reviews. 2 (3): CD011255. doi:10.1002/14651858.CD011255.pub2. PMC 6464524. PMID 26866804.
  93. ^ McGloin H, Devane D, McIntosh CD, Winkley K, Gethin G (February 2021). "Psychological interventions for treating foot ulcers, and preventing their recurrence, in people with diabetes". The Cochrane Database of Systematic Reviews. 2021 (2): CD012835. doi:10.1002/14651858.cd012835.pub2. PMC 8095008. PMID 35653236.
  94. ^ Blumberg SN, Berger A, Hwang L, Pastar I, Warren SM, Chen W (April 2012). "The role of stem cells in the treatment of diabetic foot ulcers". Diabetes Research and Clinical Practice. 96 (1): 1–9. doi:10.1016/j.diabres.2011.10.032. PMID 22142631.
  95. ^ Di Rocco G, Gentile A, Antonini A, Ceradini F, Wu JC, Capogrossi MC, Toietta G (December 2010). "Enhanced healing of diabetic wounds by topical administration of adipose tissue-derived stromal cells overexpressing stromal-derived factor-1: biodistribution and engraftment analysis by bioluminescent imaging". Stem Cells International. 2011: 304562. doi:10.4061/2011/304562. PMC 3014681. PMID 21234108.
  96. ^ Lavigne JP, Sotto A, Dunyach-Remy C, Lipsky BA (January 2015). "New Molecular Techniques to Study the Skin Microbiota of Diabetic Foot Ulcers". Advances in Wound Care. 4 (1): 38–49. doi:10.1089/wound.2014.0532. PMC 4281861. PMID 25566413.
  97. ^ Basu Mallik S, Jayashree BS, Shenoy RR (May 2018). "Epigenetic modulation of macrophage polarization- perspectives in diabetic wounds". Journal of Diabetes and Its Complications. 32 (5): 524–530. doi:10.1016/j.jdiacomp.2018.01.015. PMID 29530315.

97.^ Jayesh Kakar https://savelegs.com/negative-pressure-wound-therapy-in-foot-infections-in-diabetics-effect-on-duration-of-antibiotic-therapy-method-negative-pressure-wound-therapy-has-be/External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Diabetic_foot_ulcer&oldid=1258449827"